Publications

  • Agarwal H., Tal P., Goldfinger N., Chattopadhyay E., Malkin D., Rotter V. & Attery A. (2024). Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts.  Cell Death and Differentiation. 2024, 31 (7):855-867.
  • Zhang L., Elkahal J., Wang T., Rimmer R., Genzelinakh A., Bassat E., Wang J., Perez D., Kain D., Lendengolts D., Winkler R., Bueno-levy H., Umansky K. B., Mishaly D., Shakked A., Miyara S., Sarusi-Portuguez A., Goldfinger N., Prior A., Morgenstern D., Levin Y., Addadi Y., Li B., Rotter V., Katz U., Tanaka E. M., Krizhanovsky V., Sarig R. & Tzahor E. (2024). Egr1 regulates regenerative senescence and cardiac repair.  Nature Cardiovascular Research. 2024, 3 (8):915-932.
  • Lü Y. Q., Cho T., Mukherjee S., Suarez C. F., Gonzalez-Foutel N. S., Malik A., Martinez S., Dervovic D., Oh R. H., Langille E., Al-Zahrani K. N., Hoeg L., Lin Z. Y., Tsai R., Mbamalu G., Rotter V., Ashton-Prolla P., Moffat J., Chemes L. B., Gingras A. C., Oren M., Durocher D. & Schramek D. (2024). Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.  Molecular Systems Biology. 2024, 20 (6):719-740.
  • Light N., Layeghifard M., Attery A., Subasri V., Zatzman M., Anderson N. D., Hatkar R., Blay S., Chen D., Novokmet A., Fuligni F., Tran J., de Borja R., Agarwal H., Waldman L., Abegglen L. M., Albertson D., Finlay J. L., Hansford J. R., Behjati S., Villani A., Gerstung M., Alexandrov L. B., Somers G. R., Schiffman J. D., Rotter V., Malkin D. & Shlien A. (2023). Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis.  Nature Communications. 2023, 14 (1).
  • Kaufman T., Nitzan E., Firestein N., Ginzberg M. B., Iyengar S., Patel N., Ben-Hamo R., Porat Z., Hunter J., Hilfinger A., Rotter V., Kafri R. & Straussman R. (2022). Visual barcodes for clonal-multiplexing of live microscopy-based assays.  Nature Communications. 2022, 13 (1).
  • Tuval A., Brilon Y., Azogy H., Moskovitz Y., Leshkowitz D., Salame T. M., Minden M. D., Tal P., Rotter V., Oren M., Kaushansky N. & Shlush L. I. (2022). Pseudo-mutant P53 is a unique phenotype of DNMT3Amutated pre-leukemia.  Haematologica. 2022, 107 (11):2548-2561.
  • Bayerl J., Ayyash M., Shani T., Manor Y. S., Gafni O., Massarwa R., Kalma Y., Aguilera-Castrejon A., Zerbib M., Amir H., Sheban D., Geula S., Mor N., Weinberger L., Naveh Tassa S., Krupalnik V., Oldak B., Livnat N., Tarazi S., Wildschutz E., Tawil S., Ashouokhi S., Lasman L., Rotter V., Hanna S., Ben-Yosef D., Novershtern N., Viukov S. & Hanna J. H. (2021). Principles of signaling pathway modulation for enhancing human naive pluripotency induction.  Cell Stem Cell. 2021, 28 (9):1549-1565.e12.
  • Stein Y., Aloni-Grinstein R. & Rotter V. (2020). Mutant p53 oncogenicity: dominant-negative or gain-of-function?.  Carcinogenesis. 2020, 41 (12):1635-1647.
  • Klug Y. A., Schwarzer R., Rotem E., Charni M., Nudelman A., Gramatica A., Zarmi B., Rotter V. & Shai Y. (2019). The HIV gp41 Fusion Protein Inhibits T-Cell Activation through the Lentiviral Lytic Peptide 2 Motif.  Biochemistry. 2019, 58 (6):818-832.
  • Lonetto G., Koifman G., Silberman A., Attery A., Solomon H., Levin-Zaidman S., Goldfinger N., Porat Z., Erez A. & Rotter V. (2019). Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy.  Cell Death and Differentiation. 2019, 26 (9):1566-1581.
  • Koifman G., Aloni-Grinstein R. & Rotter V. (2019). p53 balances between tissue hierarchy and anarchy.  Journal of Molecular Cell Biology. 2019, 11 (7):553-563.
  • Stein Y., Aloni-Grinstein R. & Rotter V. (2019). Mutant p53-a potential player in shaping the tumor-stroma crosstalk.  Journal of Molecular Cell Biology. 2019, 11 (7):600-604.
  • Koifman G., Aloni-Grinstein R. & Rotter V. (2019). Corrigendum to 'p53 balances between tissue hierarchy and anarchy'.  Journal of Molecular Cell Biology. 2019, 11 (12):1106-1106.
  • Charni-Natan M., Aloni-Grinstein R., Osher E. & Rotter V. (2019). Liver and Steroid Hormones - Can a Touch of p53 Make a Difference?.  Frontiers in Endocrinology. 2019, 10 .
  • Stein Y., Rotter V. & Aloni-Grinstein R. (2019). Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.  International Journal of Molecular Sciences. 2019, 20 (24).
  • Solomon H., Dinowitz N., Pateras I. S., Cooks T., Shetzer Y., Molchadsky A., Charni M., Rabani S., Koifman G., Tarcic O., Porat Z., Kogan-Sakin I., Goldfinger N., Oren M., Harris C. C., Gorgoulis V. G. & Rotter V. (2018). Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.  Oncogene. 2018, 37 (12):1669-1684.
  • Charni-Natan M., Solomon H., Molchadsky A., Jacob-Berger A., Goldfinger N. & Rotter V. (2018). Various stress stimuli rewire the profile of liver secretome in a p53-dependent manner.  Cell Death and Disease. 2018, 9 .
  • Koifman G., Shetzer Y., Eizenberger S., Solomon H., Rotkopf R., Molchadsky A., Lonetto G., Goldfinger N. & Rotter V. (2018). A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.  Cancer Research. 2018, 78 (20):5833-5847.
  • Rotem E., Faingold O., Charni M., Klug Y. A., Harari D., Shmuel-Galia L., Nudelman A., Rotter V. & Shai Y. (2018). The HTLV-1 gp21 fusion peptide inhibits antigen specific T-cell activation in-vitro and in mice.  PLoS Pathogens. 2018, 14 (5).
  • Aloni-Grinstein R., Charni-Natan M., Solomon H. & Rotter V. (2018). p53 and the Viral Connection: Back into the Future.  Cancers. 2018, 10 (6).
  • Shetzer Y., Napchan Y., Kaufman T., Molchadsky A., Tal P., Goldfinger N. & Rotter V. (2017). Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.  International Journal of Cancer. 2017, 140 (6):1364-1369.
  • Isaac R., Goldstein I., Furth N., Zilber N., Streim S., Boura-Halfon S., Elhanany E., Rotter V., Oren M. & Zick Y. (2017). TM7SF3, a novel p53-regulated homeostatic factor, attenuates cellular stress and the subsequent induction of the unfolded protein response.  Cell Death and Differentiation. 2017, 24 (1):132-143.
  • Charni M., Aloni-Grinstein R., Molchadsky A. & Rotter V. (2017). P53 on the crossroad between regeneration and cancer.  Cell Death and Differentiation. 2017, 24 (1):8-14.
  • Solomon H., Brauning B., Fainer I., Ben-Nissan G., Rabani S., Goldfinger N., Moscovitz O., Shakked Z., Rotter V. & Sharon M. (2017). Post-translational regulation of p53 function through 20S proteasome-mediated cleavage.  Cell Death and Differentiation. 2017, 24 :2187-2198.
  • Wortzel I., Koifman G., Rotter V., Seger R. & Porat Z. (2017). High Throughput Analysis of Golgi Structure by Imaging Flow Cytometry.  Scientific Reports. 2017, 7 (1).
  • Vyas P., Beno I., Xi Z., Stein Y., Golovenko D., Kessler N., Rotter V., Shakked Z. & Haran T. E. (2017). Diverse p53/DNA binding modes expand the repertoire of p53 response elements.  Proceedings of the National Academy of Sciences of the United States of America. 2017, 114 (40):10624-10629.
  • Charni M., Molchadsky A., Goldstein I., Solomon H., Tal P., Goldfinger N., Yang P., Porat Z., Lozano G. & Rotter V. (2016). Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation.  Cell Death and Differentiation. 2016, 23 (3):509-520.
  • Grespi F., Landré V., Molchadsky A., Di Daniele N., Marsella L. T., Melino G. & Rotter V. (2016). Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells.  Cell Death & Disease. 2016, 7 (12).
  • Morel M., Shtrahman R., Rotter V., Nissim L. & Bar-Ziv R. H. (2016). Cellular heterogeneity mediates inherent sensitivity-specificity tradeoff in cancer targeting by Synthetic circuits.  Proceedings of the National Academy of Sciences of the United States of America. 2016, 113 (29):8133-8138.
  • Shetzer Y., Molchadsky A. & Rotter V. (2016). Oncogenic mutant p53 gain of function nourishes the vicious cycle of tumor development and cancer stem-cell formation.  Cold Spring Harbor perspectives in medicine. 2016, 6 (10).
  • Oren M., Tal P. & Rotter V. (2016). Targeting mutant p53 for cancer therapy.  AGING-US. 2016, 8 (6):1159-1160.
  • Tal P., Eizenberger S., Cohen E., Goldfinger N., Pietrokovski S., Oren M. & Rotter V. (2016). Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.  Oncotarget. 2016, 7 (11):11817-11837.
  • Rivlin N., Koifman G. & Rotter V. (2015). P53 orchestrates between normal differentiation and cancer.  Seminars in Cancer Biology. 2015, 32 :10-17.
  • Aloni-Grinstein R., Shetzer Y., Kaufman T. & Rotter V. (2014). P53: The barrier to cancer stem cell formation.  FEBS Letters. 2014, 588 (16):2580-2589.
  • Shetzer Y., Kagan S., Koifman G., Sarig R., Kogan-Sakin I., Charni M., Kaufman T., Zapatka M., Molchadsky A., Rivlin N., Dinowitz N., Levin S., Landan G., Goldstein I., Goldfinger N., Pe'er D., Radlwimmer B., Lichter P., Rotter V. & Aloni-Grinstein R. (2014). The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.  Cell Death and Differentiation. 2014, 21 (9):1419-1431.
  • Solomon H., Sharon M. & Rotter V. (2014). Modulation of alternative splicing contributes to cancer development: Focusing on p53 isoforms, p53β and p53γ.  Cell Death and Differentiation. 2014, 21 (9):1347-1349.
  • Rivlin N., Katz S., Doody M., Sheffer M., Horesh S., Molchadsky A., Koifman G., Shetzer Y., Goldfinger N., Rotter V. & Geiger T. (2014). Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.  Proceedings of the National Academy of Sciences of the United States of America. 2014, 111 (19):7006-7011.
  • Xiong S., Tu H., Kollareddy M., Pant V., Li Q., Zhang Y., Jackson J. G., Suh Y. A., Elizondo-Fraire A. C., Yang P., Chau G., Tashakori M., Wasylishen A. R., Ju Z., Solomon H., Rotter V., Liu B., El-Naggar A. K., Donehower L. A., Martinez L. A. & Lozano G. (2014). Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.  Proceedings of the National Academy of Sciences of the United States of America. 2014, 111 (30):11145-11150.
  • Shaulsky G., Goldfinger N., Ben-ze'ev A. & Rotter V. (2014). Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis.  Journal of General Physiology. 2014, 143 (5):645-656.
  • Shetzer Y., Solomon H., Koifman G., Molchadsky A., Horesh S. & Rotter V. (2014). The paradigm of mutant p53-expressing cancer stem cells and drug resistance.  Carcinogenesis. 2014, 35 (6):1196-1208.
  • Vidic S., Esser N., de Hoogt H. R., Verberne I., Kogan-Sakin I., Stein Y., Rotter V., Barbier M., Chong Y., Breucker S., Smans K., Akerfelt M., Nees M., King P., Hickson I., van Weerden W. W. & Graeser R. (2014). Complex in vitro and in vivo prostate cancer models for the PREDECT consortium.  Cancer Research. 2014, 74 (19).
  • Hellem M., Olsen J., Hua Y., Qu Y., Marvyin K., Rostad K., Liu J., Li L., Rotter V., Lin B., Ke X., Oyan A. & Kalland K. (2014). Restriction of androgen receptor and target gene expression.  Cancer Research. 2014, 74 (19).
  • Leibovich-Rivkin T., Liubomirski Y., Meshel T., Abashidze A., Brisker D., Solomon H., Rotter V., Weil M. & Ben-Baruch A. (2014). The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells.  BMC Cancer. 2014, 14 (1).
  • Chang F., Lemmon C. A., Nilaratanakul V., Rotter V. & Romer L. (2014). Endothelial Matrix Assembly during Capillary Morphogenesis: Insights from Chimeric TagRFP-Fibronectin Matrix.  Journal Of Histochemistry & Cytochemistry. 2014, 62 (11):774-790.
  • Cooks T., Pateras I. S., Tarcic O., Solomon H., Schetter A. J., Wilder S., Lozano G., Pikarsky E., Forshew T., Rozenfeld N., Harpaz N., Itzkowitz S., Harris C. C., Rotter V., Gorgoulis V. G. & Oren M. (2013). Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer.  Cancer Cell. 2013, 23 (5):634-646.
  • Madar S., Goldstein I. & Rotter V. (2013). 'Cancer associated fibroblasts' - more than meets the eye.  Trends in Molecular Medicine. 2013, 19 (8):447-453.
  • Brosh R., Assia-Alroy Y., Molchadsky A., Bornstein C., Dekel E., Madar S., Shetzer Y., Rivlin N., Goldfinger N., Sarig R. & Rotter V. (2013). P53 Counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition.  Cell Death and Differentiation. 2013, 20 (2):312-320.
  • Molchadsky A., Ezra O., Amendola P. G., Krantz D., Kogan-Sakin I., Buganim Y., Rivlin N., Goldfinger N., Folgiero V., Falcioni R., Sarig R. & Rotter V. (2013). P53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity.  Cell Death and Differentiation. 2013, 20 (5):774-783.
  • Goldstein I., Rivlin N., Shoshana O., Ezra O., Madar S., Goldfinger N. & Rotter V. (2013). Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3a4 by activating p53.  Carcinogenesis. 2013, 34 (1):190-198.
  • Madar S., Harel E., Goldstein I., Stein Y., Kogan-Sakin I., Kamer I., Solomon H., Dekel E., Tal P., Goldfinger N., Friedlander G. & Rotter V. (2013). Mutant p53 Attenuates the Anti-Tumorigenic Activity of Fibroblasts-Secreted Interferon Beta.  PLoS ONE. 2013, 8 (4).
  • Olsen J. R., Oyan A. M., Rostad K., Hellem M. R., Liu J., Li L., Micklem D. R., Haugen H., Lorens J. B., Rotter V., Ke X. S., Lin B. & Kalland K. H. (2013). p63 Attenuates Epithelial to Mesenchymal Potential in an Experimental Prostate Cell Model.  PLoS ONE. 2013, 8 (5).
  • Goldstein I., Ezra O., Rivlin N., Molchadsky A., Madar S., Goldfinger N. & Rotter V. (2012). P53, a novel regulator of lipid metabolism pathways.  Journal of Hepatology. 2012, 56 (3):656-662.
  • Goldstein I., Madar S. & Rotter V. (2012). Cancer research, a field on the verge of a paradigm shift?.  Trends in Molecular Medicine. 2012, 18 (6):299-303.
  • Goldstein I. & Rotter V. (2012). Regulation of lipid metabolism by p53 - fighting two villains with one sword.  Trends in Endocrinology and Metabolism. 2012, 23 (11):567-575.
  • Blandino G., Deppert W., Hainaut P., Levine A., Lozano G., Olivier M., Rotter V., Wiman K. & Oren M. (2012). Mutant p53 protein, master regulator of human malignancies: A report on the fifth Mutant p53 Workshop.  Cell Death and Differentiation. 2012, 19 (1):180-183.
  • Landan G., Cohen N. M., Mukamel Z., Bar A., Molchadsky A., Brosh R., Horn-Saban S., Zalcenstein D. A., Goldfinger N., Zundelevich A., Gal-Yam E. N., Rotter V. & Tanay A. (2012). Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues.  Nature Genetics. 2012, 44 (11):1207-1214.
  • Kravchenko-Balasha N., Levitzki A., Goldstein A., Rotter V., Remacle F. & Levine R. D. (2012). On a fundamental structure of gene networks in living cells.  Proceedings of the National Academy of Sciences of the United States of America. 2012, 109 (12):4702-4707.
  • Heidegger I., Ofer P., Doppler W., Rotter V., Klocker H. & Massoner P. (2012). Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells.  Endocrinology. 2012, 153 (10):4633-4643.
  • Solomon H., Buganim Y., Kogan-Sakin I., Pomeraniec L., Assia Y., Madar S., Goldstein I., Brosh R., Kalo E., Beatus T., Goldfinger N. & Rotter V. (2012). Various p53 mutant proteins differently regulate the ras circuit to induce a cancer-related gene signature.  Journal of Cell Science. 2012, 125 (13):3144-3152.
  • Kalo E., Kogan-Sakin I., Solomon H., Bar-Nathan E., Shay M., Shetzer Y., Dekel E., Goldfinger N., Buganim Y., Stambolsky P., Goldstein I., Madar S. & Rotter V. (2012). Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.  Journal of Cell Science. 2012, 125 (22):5578-5586.
  • Leibovich-Rivkin T., Buganim Y., Solomon H., Meshel T., Rotter V. & Ben-Baruch A. (2012). Tumor-promoting circuits that regulate a cancer-related chemokine cluster: Dominance of inflammatory mediators over oncogenic alterations.  Cancers. 2012, 4 (1):55-76.
  • Solomon H., Madar S. & Rotter V. (2011). Mutant p53 gain of function is interwoven into the hallmarks of cancer.  Journal of Pathology. 2011, 225 (4):475-478.
  • Ke X. s., Li W. c., Hovland R., Qu Y., Liu R. h., McCormack E., Thorsen F., Olsen J. R., Molven A., Kogan-Sakin I., Rotter V., Akslen L. A., Oyan A. M. & Kalland K. H. (2011). Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model.  Experimental Cell Research. 2011, 317 (2):234-247.
  • Sarig R. & Rotter V. (2011). Editorial: Can an iPS cell secure its genomic fidelity.  Cell Death and Differentiation. 2011, 18 (5):743-744.
  • Goldstein I., Marcel V., Olivier M., Oren M., Rotter V. & Hainaut P. (2011). Understanding wild-type and mutant p53 activities in human cancer: New landmarks on the way to targeted therapies.  Cancer Gene Therapy. 2011, 18 (1):2-11.
  • Dell'Orso S., Fontemaggi G., Stambolsky P., Goeman F., Voellenkle C., Levrero M., Strano S., Rotter V., Oren M. & Blandino G. (2011). ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters.  Omics-A Journal Of Integrative Biology. 2011, 15 (5):305-312.
  • Buganim Y., Madar S., Rais Y., Pomeraniec L., Harel E., Solomon H., Kalo E., Goldstein I., Brosh R., Haimov O., Avivi C., Polak-Charcon S., Goldfinger N., Barshack I. & Rotter V. (2011). Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression.  Carcinogenesis. 2011, 32 (12):1749-1757.
  • Bornstein C., Brosh R., Molchadsky A., Madar S., Kogan-Sakin I., Goldstein I., Chakravarti D., Flores E. R., Goldfinger N., Sarig R. & Rotter V. (2011). SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63.  Molecular and Cellular Biology. 2011, 31 (8):1679-1689.
  • Kravchenko-Balasha N., Remacle F., Gross A., Rotter V., Levitzki A. & Levine R. D. (2011). Convergence of Logic of Cellular Regulation in Different Premalignant Cells by an Information Theoretic Approach.  BMC Systems Biology. 2011, 5 .
  • Rinon A., Molchadsky A., Nathan E., Yovel G., Rotter V., Sarig R. & Tzahor E. (2011). P53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes.  Development. 2011, 138 (9):1827-1838.
  • Tabach Y., Kogan-Sakin I., Buganim Y., Solomon H., Goldfinger N., Hovland R., Ke X., Oyan A. M., Kalland K., Rotter V. & Domany E. (2011). Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer.  PLoS ONE. 2011, 6 (1).
  • Leshem O., Madar S., Kogan-Sakin I., Kamer I., Goldstein I., Brosh R., Cohen Y., Jacob-Hirsch J., Ehrlich M., Ben-Sasson S., Goldfinger N., Loewenthal R., Gazit E., Rotter V. & Berger R. (2011). TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model.  PLoS ONE. 2011, 6 (7).
  • Madar S., Solomon H. & Rotter V. (2011). Same stem cells but different: Isogenic embryonic stem cells harboring different p53 mutants.  Cell Cycle. 2011, 10 (14):2248.
  • Madar S., Goldstein I., Neeman O. & Rotter V. (2011). Beyond tumor suppression: p53 controls blastocyst implantation.  Cell Cycle. 2011, 10 (24):4203.
  • Madar S., Stambolsky P. & Rotter V. (2011). Unleash the wild type: Restoration of p53 suppressive activity in skin cancer.  Cell Cycle. 2011, 10 (5):741-740.
  • Solomon H., Brosh R., Buganim Y. & Rotter V. (2010). Inactivation of the p53 Tumor Suppressor Gene and Activation of the Ras Oncogene: Cooperative Events in Tumorigenesis.  Discovery medicine. 2010, 48 :448-454.
  • Stambolsky P., Tabach Y., Fontemaggi G., Weisz L., Maor-Aloni R., Sigfried Z., Shiff I., Kogan I., Shay M., Kalo E., Blandino G., Simon I., Oren M. & Rotter V. (2010). Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53.  Cancer Cell. 2010, 17 (3):273-285.
  • Brosh R., Sarig R., Bar Natan N. E., Molchadsky A., Madar S., Bornstein C., Buganim Y., Shapira T., Goldfinger N., Paus R. & Rotter V. (2010). P53-dependent transcriptional regulation of EDA2R and its involvement in chemotherapy-induced hair loss.  FEBS Letters. 2010, 584 (11):2473-2477.
  • Sarig R., Rivlin N., Brosh R., Bornstein C., Kamer I., Ezra O., Molchadsky A., Goldfinger N., Brenner O. & Rotter V. (2010). Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.  Journal of Experimental Medicine. 2010, 207 (10):2127-2140.
  • Molchadsky A., Rivlin N., Brosh R., Rotter V. & Sarig R. (2010). P53 is balancing development, differentiation and de-differentiation to assure cancer prevention.  Carcinogenesis. 2010, 31 (9):1501-1508.
  • Oren M. & Rotter V. (2010). Mutant p53 gain-of-function in cancer..  Cold Spring Harbor perspectives in biology. 2010, 2 (2):a001107.
  • Buganim Y., Solomon H., Rais Y., Kistner D., Nachmany I., Brait M., Madar S., Goldstein I., Kalo E., Adam N., Gordin M., Rivlin N., Kogan I., Brosh R., Sefadia-Elad G., Goldfinger N., Sidransky D., Kloog Y. & Rotter V. (2010). p53 regulates the ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.  Cancer Research. 2010, 70 (6):2274-2284.
  • Ke X. S., Qu Y., Cheng Y., Li W. C., Rotter V., Øyan A. M. & Kalland K. H. (2010). Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells.  BMC Genomics. 2010, 11 (1).
  • Buganim Y., Goldstein I., Lipson D., Milyavsky M., Polak-Charcon S., Mardoukh C., Solomon H., Kalo E., Madar S., Brosh R., Perelman M., Navon R., Goldfinger N., Barshack I., Yakhini Z. & Rotter V. (2010). A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype.  PLoS ONE. 2010, 5 (3).
  • Shalgi R., Brosh R., Oren M., Pilpel Y. & Rotter V. (2009). Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fate.  AGING-US. 2009, 1 (9):762-770.
  • Daniel-Carmi V., Makovitzki-Avraham E., Reuven E., Goldstein I., Zilkha N., Rotter V., Tzehoval E. & Eisenbach L. (2009). The human 1-8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene.  International Journal of Cancer. 2009, 125 (12):2810-2819.
  • Peller S., Tabach Y., Rotschild M., Garach-Joshua O., Cohen Y., Goldfinger N. & Rotter V. (2009). Identification of gene networks associated with erythroid differentiation.  Blood Cells Molecules And Diseases. 2009, 43 (1):74-80.
  • Marrazzo E., Marchini S., Tavecchio M., Alberio T., Previdi S., Erba E., Rotter V. & Broggini M. (2009). The expression of the ΔNp73β isoform of p73 leads to tetraploidy.  European Journal of Cancer. 2009, 45 (3):443-453.
  • Suad O., Rozenberg H., Brosh R., Diskin Posner Y., Kessler N., Shimon L. J. W., Frolow F., Liran A., Rotter V. & Shakked Z. (2009). Structural Basis of Restoring Sequence-Specific DNA Binding and Transactivation to Mutant p53 by Suppressor Mutations.  Journal of Molecular Biology. 2009, 385 (1):249-265.
  • Zemach A., Paul L. K., Stambolsky P., Efroni I., Rotter V. & Grafi G. (2009). The C-terminal domain of the Arabidopsis AtMBD7 protein confers strong chromatin binding activity.  Experimental Cell Research. 2009, 315 (20):3554-3562.
  • Buganim Y. & Rotter V. (2009). p53: Balancing tumour suppression and implications for the clinic.  European Journal of Cancer. 2009, 45 (SUPPL. 1):217-234.
  • Brosh R. & Rotter V. (2009). When mutants gain new powers: News from the mutant p53 field.  Nature Reviews Cancer. 2009, 9 (10):701-713.
  • Bar J., Feniger-Barish R., Lukashchuk N., Shaham H., Moskovits N., Goldfinger N., Simansky D., Perlman M., Papa M., Yosepovich A., Rechavi G., Rotter V. & Oren M. (2009). Cancer cells suppress p53 in adjacent fibroblasts.  Oncogene. 2009, 28 (6):933-936.
  • Yuan J., Yang B. M., Zhong Z., Shats I., Milyavsky M., Rotter V., Lock R. B., Reddel R. R. & MacKenzie K. L. (2009). Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase.  Oncogene. 2009, 28 (29):2678-2689.
  • Aylon Y., Yabuta N., Besserglick H., Buganim Y., Rotter V., Nojima H. & Oren M. (2009). Silencing of the lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation.  Oncogene. 2009, 28 (50):4469-4479.
  • Brosh R. & Rotter V. (2009). Transcriptional control of the proliferation cluster by the tumor suppressor p53.  Molecular BioSystems. 2009, 6 (1):17-29.
  • Madar S., Brosh R., Buganim Y., Ezra O., Goldstein I., Solomon H., Kogan I., Goldfinger N., Klocker H. & Rotter V. (2009). Modulated expression of WFDC1 during carcinogenesis and cellular senescence.  Carcinogenesis. 2009, 30 (1):20-27.
  • Kogan-Sakin I., Cohen M., Paland N., Madar S., Solomon H., Molchadsky A., Brosh R., Buganim Y., Goldfinger N., Klocker H., Schalken J. A. & Rotter V. (2009). Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1.  Carcinogenesis. 2009, 30 (4):698-705.
  • Madar S., Goldstein I. & Rotter V. (2009). Did Experimental Biology Die? Lessons from 30 Years of p53 Research.  Cancer Research. 2009, 69 (16):6378-6380.
  • Paland N., Kamer I., Kogan-Sakin I., Madar S., Goldfinger N. & Rotter V. (2009). Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer.  Molecular Cancer Research. 2009, 7 (8):1212-1223.
  • Ke X., Qu Y., Rostad K., Li W., Lin B., Halvorsen O. J., Haukaas S. A., Jonassen I., Petersen K., Goldfinger N., Rotter V., Akslen L. A., Oyan A. M. & Kalland K. (2009). Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.  PLoS ONE. 2009, 4 (3).
  • Lavelin I., Beer A., Kam Z., Rotter V., Oren M., Navon A. & Geiger B. (2009). Discovery of novel proteasome inhibitors using a high-content cell-based screening system.  PLoS ONE. 2009, 4 (12).
  • Brosh R., Shalgi R., Liran A., Landan G., Korotayev K., Nguyen G. H., Enerly E., Johnsen H., Buganim Y., Solomon H., Goldstein I., Madar S., Goldfinger N., Brresen-Dale A., Ginsberg D., Harris C. C., Pilpel Y., Oren M. & Rotter V. (2008). p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation.  Molecular Systems Biology. 2008, 4 .
  • Salah Z., Haupt S., Maoz M., Baraz L., Rotter V., Peretz T., Haupt Y. & Bar-Shavit R. (2008). p53 controls hPar1 function and expression.  Oncogene. 2008, 27 (54):6866-6874.
  • Ke X., Qu Y., Goldfinger N., Rostad K., Hovland R., Akslen L. A., Rotter V., Oyan A. M. & Kalland K. (2008). Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation.  PLoS ONE. 2008, 3 (10).
  • Molchadsky A., Shats I., Goldfinger N., Pevsner-Fischer M., Olson M., Rinon A., Tzahor E., Lozano G., Zipori D., Sarig R. & Rotter V. (2008). P53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner.  PLoS ONE. 2008, 3 (11):1-15.
  • Bossi G., Marampon F., Maor-Aloni R., Zani B., Rotter V., Oren M., Strano S., Blandino G. & Sacchi A. (2008). Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.  Cell Cycle. 2008, 7 (12):1870-1879.
  • Buganim Y. & Rotter V. (2008). RHAMM in the complex p53 cell cycle network.  Cell Cycle. 2008, 7 (21):3287-3291.
  • Milyavsky M., Shats I., Cholostoy A., Brosh R., Buganim Y., Weisz L., Kogan I., Cohen M., Shatz M., Madar S., Kalo E., Goldfinger N., Yuan J., Ron S., MacKenzie K., Eden A. & Rotter V. (2007). Inactivation of Myocardin and p16 during Malignant Transformation Contributes to a Differentiation Defect.  Cancer Cell. 2007, 11 (2):133-146.
  • Weisz L., Oren M. & Rotter V. (2007). Transcription regulation by mutant p53.  Oncogene. 2007, 26 (15):2202-2211.
  • Tang X., Milyavsky M., Goldfinger N. & Rotter V. (2007). Amyloid-β precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress.  Oncogene. 2007, 26 (52):7302-7312.
  • Efrati S., Berman S., Goldfinger N., Erez N., Averbukh Z., Golik A., Rotter V. & Weissgarten J. (2007). Enhanced angiotensin II production by renal mesangium is responsible for apoptosis/proliferation of endothelial and epithelial cells in a model of malignant hypertension.  Journal of Hypertension. 2007, 25 (5):1041-1052.
  • Kalo E., Buganim Y., Shapira K. E., Besserglick H., Goldfinger N., Weisz L., Stambolsky P., Henis Y. I. & Rotter V. (2007). Mutant p53 attenuates the SMAD-dependent transforming growth factor β1 (TGF-β1) signaling pathway by repressing the expression of TGF-β receptor type II.  Molecular and Cellular Biology. 2007, 27 (23):8228-8242.
  • Weisz L., Damalas A., Liontos M., Karakaidos P., Fontemaggi G., Maor-Aloni R., Kalis M., Levrero M., Strano S., Gorgoulis V. G., Rotter V., Blandino G. & Oren M. (2007). Mutant p53 enhances nuclear factor κB activation by tumor necrosis factor α in cancer cells.  Cancer Research. 2007, 67 (6):2396-2401.
  • Tabach Y., Brosh R., Buganim Y., Reiner A., Zuk O., Yitzhaky A., Koudritsky M., Rotter V. & Domany E. (2007). Wide-scale analysis of human functional transcription factor binding reveals a strong bias towards the transcription start site.  PLoS ONE. 2007, 2 (8).
  • Shats I., Milyavsky M., Cholostoy A., Brosh R. & Rotter V. (2007). Myocardin in tumor suppression and myofibroblast differentiation.  Cell Cycle. 2007, 6 (10):1141-1146.
  • Walma T. & Rotter V. (2006). Spotlight on . . . Varda Rotter.  FEBS Letters. 2006, 580 (20):4763-4763.
  • Rentsch C. A., Germann M., Wetterwald A., Schwaninger R., Voller M., Rotter V., Oren M., Schalken J. A., Studer U. E., Thalmann G. N. & Cecchini M. G. (2006). Transforming growth factor stimulated clone 22 (TSC-22): Potential tumor suppressive role in prostate cancer and novel prostate basal cell marker.  European Urology Supplements. 2006, 5 (14):790-790.
  • Verhaegh G. W., Kogan I., Kensch P., Vandenoudenalder K., Smit F., Huynen M., Rotter V. & Schalken J. A. (2006). PCA/DD3, a protein-binding non-coding RNA with oncogenic properties.  European Urology Supplements. 2006, 5 (14):791-791.
  • Stambolsky P., Weisz L., Shats I., Klein Y. A., Goldfinger N., Oren M. & Rotter V. (2006). Regulation of AIF expression by p53.  Cell Death and Differentiation. 2006, 13 (12):2140-2149.
  • Zalcenstein A., Weisz L., Stambolsky P., Bar J., Rotter V. & Oren M. (2006). Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.  Oncogene. 2006, 25 (3):359-369.
  • Kogan I., Goldfinger N., Milyavsky M., Cohen M., Shats I., Dobler G., Klocker H., Wasylyk B., Voller M., Aalders T., Schalken J., Oren M. & Rotter V. (2006). hTERT-immortalized prostate epithelial and stromal-derived cells: An authentic in vitro model for differentiation and carcinogenesis.  Cancer Research. 2006, 66 (7):3531-3540.
  • Buganim Y., Kalo E., Brosh R., Besserglick H., Nachmany I., Rais Y., Stambolsky P., Tang X., Milyavsky M., Shats I., Kalis M., Goldfinger N. & Rotter V. (2006). Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction.  Cancer Research. 2006, 66 (22):10750-10759.
  • Orgad S., Goldfinger N., Cohen G., Rotter V. & Solomon B. (2005). Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein.  FEBS Letters. 2005, 579 (25):5609-5615.
  • Tabach Y., Milyavsky M., Shats I., Brosh R., Zuk O., Yitzhaky A., Mantovani R., Domany E., Rotter V. & Pilpel Y. (2005). The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation..  Molecular Systems Biology. 2005, 1 :2005.0022.
  • Milyavsky M., Tabach Y., Shats I., Erez N., Cohen Y., Tang X., Kalis M., Kogan I., Buganim Y., Goldfinger N., Ginsberg D., Harris C., Domany E. & Rotter V. (2005). Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation.  Cancer Research. 2005, 65 (11):4530-4543.
  • Damalas A., Weis L., Nordgard S., Kristensen V., Gardner K., Cheng G., Gelinas C., Levrero M., Strano S., Borresen-Dale A., Rotter V., Oren M. & Blandino G. (2005). Mutant p53 exerts its gain of function through activation of the NF-kappa B pathway.  Breast Cancer Research. 2005, 7 :S53-S53.
  • Herkel J., Kam N., Erez N., Mimran A., Heifetz A., Eisenstein M., Rotter V. & Cohen L. (2004). Monoclonal antibody to a DNA-binding domain of p53 mimics charge structure of DNA: Anti-idiotypes to the anti-p53 antibody are anti-DNA.  European Journal of Immunology. 2004, 34 (12):3623-3632.
  • Erez N., Stambolsky P., Shats I., Milyavsky M., Kachko T. & Rotter V. (2004). Hypoxia-dependent regulation of PHD1: Cloning and characterization of the human PHD1/EGLN2 gene promoter.  FEBS Letters. 2004, 567 (2-3):311-315.
  • Meerson A., Milyavsky M. & Rotter V. (2004). p53 mediates density-dependent growth arrest.  FEBS Letters. 2004, 559 (1-3):152-158.
  • Matas D., Milyavsky M., Shats I., Nissim L., Goldfinger N. & Rotter V. (2004). p53 is a regulator of macrophage differentiation.  Cell Death and Differentiation. 2004, 11 (4):458-467.
  • Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N. & Rotter V. (2004). Activated p53 suppresses the histone methyltransferase EZH2 gene.  Oncogene. 2004, 23 (34):5759-5769.
  • Shats I., Milyavsky M., Tang X., Stambolsky P., Erez N., Brosh R., Kogan I., Braunstein I., Tzukerman M., Ginsberg D. & Rotter V. (2004). p53-dependent down-regulation of telomerase is mediated by p21 waf1.  Journal of Biological Chemistry. 2004, 279 (49):50976-50985.
  • Zurer I., Hofseth L., Cohen Y., Xu-Welliver M., Hussain S., Harris C. & Rotter V. (2004). The role of p53 in base excision repair following genotoxic stress.  Carcinogenesis. 2004, 25 (1):11-19.
  • Weisz L., Zalcenstein A., Stambolsky P., Cohen Y., Goldfinger N., Oren M. & Rotter V. (2004). Transactivation of the EGR1 gene contributes to mutant p53 gain of function.  Cancer Research. 2004, 64 (22):8318-8327.
  • Mimran A., Mor F., Carmi P., Quintana F., Rotter V. & Cohen I. R. (2004). DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response.  Journal of Clinical Investigation. 2004, 113 (6):924-932.
  • Milyavsky M., Shats I., Erez N., Tang X., Senderovich S., Meerson A., Tabach Y., Goldfinger N., Ginsberg D., Harris C. & Rotter V. (2003). Prolonged Culture of Telomerase-Immortalized Human Fibroblasts Leads to a Premalignant Phenotype.  Cancer Research. 2003, 63 (21):7147-7157.
  • Erez N., Milyavsky M., Eilam R., Shats G., Goldfinger N. & Rotter V. (2003). Expression of Prolyl-Hydroxylase-1 (PHD1/EGLN2) Suppresses Hypoxia Inducible Factor-1α Activation and Inhibits Tumor Growth.  Cancer Research. 2003, 63 (24):8777-8783.
  • Peller S. & Rotter V. (2003). TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance.  Human Mutation. 2003, 21 (3):277-284.
  • Shats I., Milyavsky M., Erez N. & Rotter V. (2003). The murine telomerase catalytic subunit shares the PAb-240 mutant specific epitope of the p53 protein.  FEBS Letters. 2003, 546 (2-3):321-324.
  • Peller S., Frenkel J., Kahn J., Rahimi-Levene N., Yona R., Nissim L., Goldfinger N., Sherman D. & Rotter V. (2003). The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts.  Oncogene. 2003, 22 (30):4648-4655.
  • Zalcenstein A., Stambolsky P., Weisz L., Muller M., Wallach D., Goncharov T., Krammer P., Rotter V. & Oren M. (2003). Mutant p53 gain of function: Repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.  Oncogene. 2003, 22 (36):5667-5676.
  • Hofseth L., Saito S., Hussain S., Espey M., Miranda K., Araki Y., Jhappan C., Higashimoto Y., He P., Linke S., Quezado M., Zurer I., Rotter V., Wink D., Appella E. & Harris C. (2003). Nitric oxide-induced cellular stress and p53 activation in chronic inflammation.  Proceedings of the National Academy of Sciences of the United States of America. 2003, 100 (1):143-148.
  • Hofseth L., Khan M., Ambrose M., Nikolayeva O., Xu-Welliver M., Kartalou M., Hussain S., Roth R., Zhou X., Mechanic L., Zurer I., Rotter V., Samson L. & Harris C. (2003). The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation.  Journal of Clinical Investigation. 2003, 112 (12):1887-1894.
  • Shakked Z., Yavnilovitch M., Kalb A., Kessler N., Wolkowicz R., Rotter V. & Haran T. (2002). DNA binding and 3-5 exonuclease activity in the murine alternatively-spliced p53 protein.  Oncogene. 2002, 21 (33):5117-5126.
  • Erez N., Milyavsky M., Goldfinger N., Peles E., Gudkov A. & Rotter V. (2002). Falkor, a novel cell growth regulator isolated by a functional genetic screen.  Oncogene. 2002, 21 (44):6713-6721.
  • Haupt Y., Robles A. I., Prives C. & Rotter V. (2002). Deconstruction of p53 functions and regulation.  Oncogene. 2002, 21 (54):8223-8231.
  • Herkel J., Modrow J., Bamberger S., Kanzler S., Rotter V., Cohen I. R. & Lohse A. (2002). Prevalence of autoantibodies to the p53 protein in autoimmune hepatitis.  Autoimmunity. 2002, 35 (8):493-496.
  • Lilling G., Nordenberg J., Rotter V., Goldfinger N., Peller S. & Sidi Y. (2002). Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells.  Cancer Investigation. 2002, 20 (4):509-517.
  • Offer H., Erez N., Zurer I., Tang X., Milyavsky M., Goldfinger N. & Rotter V. (2002). The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA.  Carcinogenesis. 2002, 23 (6):1025-1032.
  • Offer H., Zurer I., Banfalvi G., Reha'k M., Falcovitz A., Milyavsky M., Goldfinger N. & Rotter V. (2001). p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress.  Cancer Research. 2001, 61 (1):88-96.
  • Herkel J., Lohse A., Mimran A., Erez N., Kam N., Marker-Hermann E., Rotter V. & Cohen I. R. (2001). Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies.  Journal of Autoimmunity. 2001, 17 (1):63-69.
  • Uberti D., Piccioni L., Cadei M., Grigolato P., Rotter V. & Memo M. (2001). p53 is dispensable for apoptosis but controls neurogenesis of mouse dentate gyrus cells following γ-irradiation.  Molecular Brain Research. 2001, 93 (1):81-89.
  • Offer H., Milyavsky M., Erez N., Matas D., Zurer I., Harris C. & Rotter V. (2001). Structural and functional involvement of p53 in BER in vitro and in vivo.  Oncogene. 2001, 20 (5):581-589.
  • Sigal A., Matas D., Almog N., Goldfinger N. & Rotter V. (2001). The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis.  Oncogene. 2001, 20 (35):4891-4898.
  • Almog N., Milyavsky M., Stambolsky F., Falcovitz A., Goldfinger N. & Rotter V. (2001). The role of the C' terminus of murine p53 in the p53/mdm-2 regulatory loop.  Carcinogenesis. 2001, 22 (5):779-785.
  • Matas D., Sigal A., Stambolsky P., Milyavsky M., Weisz L., Schwartz D., Goldfinger N. & Rotter V. (2001). Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.  EMBO Journal. 2001, 20 (15):4163-4172.
  • Milyavsky M., Mimran A., Senderovich S., Zurer I., Erez N., Shats I., Goldfinger N., Cohen I. & Rotter V. (2001). Activation of p53 protein by telomeric (TTAGGG)n repeats.  Nucleic Acids Research. 2001, 29 (24):5207-5215.
  • Seluanov A., Gorbunova V., Falcovitz A., Sigal A., Milyavsky M., Zurer I., Shohat G., Goldfinger N. & Rotter V. (2001). Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53.  Molecular and Cellular Biology. 2001, 21 (5):1552-1564.
  • Sigal A. & Rotter V. (2000). Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome.  Cancer Research. 2000, 60 (24):6788-6793.
  • Herkel J., Erez-Alon N., Mimran A., Wolkowicz R., Harmelin A., Ruiz P., Rotter V. & Cohen I. R. (2000). Systemic lupus erythematosus in mice, spontaneous and induced, is associated with autoimmunity to the C-terminal domain of p53 that recognizes damaged DNA.  European Journal of Immunology. 2000, 30 (4):977-984.
  • Lilling G., Hacohen H., Nordenberg J., Livnat T., Rotter V. & Sidi Y. (2000). Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: Possible relation to high bcl-2/bax ratio?.  Cancer Letters. 2000, 161 (1):27-34.
  • Almog N., Goldfinger N. & Rotter V. (2000). p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53.  Oncogene. 2000, 19 (30):3395-3403.
  • Homburg S., Visochek L., Moran N., Dantzer F., Priel E., Asculai E., Schwartz D., Rotter V., Dekel N. & Cohen-Armon M. (2000). A fast signal-induced activation of poly(ADP-ribose) polymerase: A novel downstream target of phospholipase C.  Journal of Cell Biology. 2000, 150 (2):293-307.
  • Schwartz D., Goldfinger N., Kam Z. & Rotter V. (1999). p53 Controls low DNA damage-dependent premeiotic checkpoint and facilitates DNA repair during spermatogenesis.  Cell Growth and Differentiation. 1999, 10 (10):665-675.
  • Sigal A., Matas D., Almog N., Li R., Sutphin P. & Rotter V. (1999). Interference of mutant p53 with drug induced apoptotic pathways.  2Nd International Congress On Gastroenterological Carcinogenesis. 1999, :211-222.
  • Peller S., Halperin R., Schneider D., Kopilova Y. & Rotter V. (1999). Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma.  Oncology Reports. 1999, 6 (1):193-197.
  • Yaron Y., Schwartz D., Evans M., Aloni R., Kapon A. & Rotter V. (1999). p53 Tumor suppresser gene expression in the mouse ovary during an artificially induced ovulatory cycle.  Journal Of Reproductive Medicine. 1999, 44 (2):107-114.
  • Zhou X., Wang X., Xu L., Hagiwara K., Nagashima M., Wolkowicz R., Zurer I., Rotter V. & Harris C. (1999). COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis.  Cancer Research. 1999, 59 (4):843-848.
  • Torchinsky A., Ivnitsky I., Savion S., Shepshelovich J., Gorivodsky M., Fein A., Carp H., Schwartz D., Frankel J., Rotter V. & Toder V. (1999). Cellular events and the pattern of p53 protein expression following cyclophosphamide-initiated cell death in various organs of developing embryo.  Teratogenesis Carcinogenesis and Mutagenesis. 1999, 19 (5):353-367.
  • Uberti D., Schwartz D., Almog N., Goldfinger N., Harmelin A., Memo M. & Rotter V. (1999). Epithelial cells of different organs exhibit distinct patterns of p53-dependent and p53-independent apoptosis following DNA insult.  Experimental Cell Research. 1999, 252 (1):123-133.
  • Oren M. & Rotter V. (1999). Introduction. p53: The first twenty years.  Cellular and Molecular Life Sciences. 1999, 55 (1):9-11.
  • Offer H., Wolkowicz R., Matas D., Blumenstein S., Livneh Z. & Rotter V. (1999). Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery.  FEBS Letters. 1999, 450 (3):197-204.
  • Uberti D., Yavin E., Gil S., Ayasola K., Goldfinger N. & Rotter V. (1999). Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin.  Molecular Brain Research. 1999, 65 (2):167-175.
  • Tendler Y., Weisinger G., Coleman R., Diamond E., Lischinsky S., Kerner H., Rotter V. & Zinder O. (1999). Tissue-specific p53 expression in the nervous system.  Molecular Brain Research. 1999, 72 (1):40-46.
  • Zhao W., He C., Rotter V., Merrick B. A. & Selkirk J. K. (1999). An intragenic deletion of nuclear localization signal-1 of p53 tumor suppressor gene results in loss of apoptosis in murine fibroblasts.  Cancer Letters. 1999, 147 (1-2):101-108.
  • Frenkel J., Sherman D., Fein A., Schwartz D., Almog N., Kapon A., Goldfinger N. & Rotter V. (1999). Accentuated apoptosis in normally developing p53 knockout mouse embryos following genotoxic stress.  Oncogene. 1999, 18 (18):2901-2907.
  • Yaron Y., Schwartz D., Evans M., Lessing J. & Rotter V. (1998). Alternatively spliced mRNA transcripts encoding the extracellular domain of the FSH receptor gene: Expression in the mouse ovary during the ovulatory cycle.  Journal Of Reproductive Medicine. 1998, 43 (5):435-438.
  • Erez-Alon N., Herkel J., Wolkowicz R., Ruiz P., Waisman A., Rotter V. & Cohen I. R. (1998). Immunity to p53 induced by an idiotypic network of anti-p53 antibodies: Generation of sequence-specific anti-DNA antibodies and protection from tumor metastasis.  Cancer Research. 1998, 58 (23):5447-5452.
  • Prokocimer M., Unger R., Rennert H., Rotter V. & Rennert G. (1998). Pooled analysis of p53 mutations in hematological malignancies.  Human Mutation. 1998, 12 (1):4-18.
  • Peller S., Yona R., Kopilova Y., Prokocimer M., Goldfinger N., Uysal A., Karabulut H., Tukun A., Bokesoy I., Tuncman G. & Rotter V. (1998). Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia.  Genes Chromosomes & Cancer. 1998, 21 (1):2-7.
  • Rotter V. (1998). The role of wild type p53 in tumor protection and its loss in tumor development and progression - Introduction.  Seminars in Cancer Biology. 1998, 8 (5):315-316.
  • Ruiz P., Wolkowicz R., Waisman A., Hirschberg D., Carmi P., Erez N., Garren H., Herkel J., Karpuj M., Steinman L., Rotter V. & Cohen I. R. (1998). Idiotypic immunization induces immunity to mutated p53 and tumor rejection.  Nature Medicine. 1998, 4 (6):710-712.
  • Li R., Sutphin P., Schwartz D., Matas D., Almog N., Wolkowicz R., Goldfinger N., Pei H., Prokocimer M. & Rotter V. (1998). Mutant p53 protein expression interferes with p53-independent apoptotic pathways.  Oncogene. 1998, 16 (25):3269-3277.
  • Wolkowicz R., Peled A., Elkind N. B. & Rotter V. (1998). DNA-binding activity of wild-type p53 protein is mediated by the central part of the molecule and controlled by its C terminus.  Cancer Detection and Prevention. 1998, 22 (1):1-13.
  • Prokocimer M., Peller S., Ben-Bassat H., Goldfinger N. & Rotter V. (1998). P53 Gene Mutation in a T-Acute Lymphoblastic Leukemia Cell Line (Loucy) with t(16:20) and 5q-Chromosomal Aberrations.  Leukemia & Lymphoma. 1998, 29 (42130):607-611.
  • Rehberger P., Richter K., Schwartz D., Goldfinger N., Oskato R., Almog N., Marks F. & Rotter V. (1997). Differential expression of the regularly spliced wild-type p53 and its COOH-terminal alternatively spliced form during epidermal differentiation.  Cell Growth and Differentiation. 1997, 8 (8):851-860.
  • Wolkowicz R. & Rotter V. (1997). The DNA binding regulatory domain of p53: See the C.  Pathologie Biologie. 1997, 45 (10):785-796.
  • Schwartz D. & Rotter V. (1997). p53-dependent cell cycle control: Response to genotoxic stress.  Seminars in Cancer Biology. 1997, 8 (5):325-336.
  • Almog N. & Rotter V. (1997). Involvement of p53 in cell differentiation and development.  Biochimica Et Biophysica Acta-Reviews On Cancer. 1997, 1333 (1):F1-F27.
  • Simons A., MelamedBessudo C., Wolkowicz R., Sperling J., Sperling R., Eisenbach L. & Rotter V. (1997). PACT: Cloning and characterization of a cellular p53 binding protein that interacts with Rb.  Oncogene. 1997, 14 (2):145-155.
  • Schwartz D., Almog N., Peled A., Goldfinger N. & Rotter V. (1997). Role of wild type p53 in the G(2) phase: regulation of the gamma-irradiation-induced delay and DNA repair.  Oncogene. 1997, 15 (21):2597-2607.
  • Sthoeger Z., Evron E., Goland S., Shani A., Wolkowicz R., Goldfinger N., Rotter V. & Fogel M. (1997). Anti-p53 autoantibodies in colon cancer patients.  B Lymphocytes And Autoimmunity. 1997, 815 :496-498.
  • Almog N., Li R., Peled A., Schwartz D., Wolkowicz R., Goldfinger N., Pei H. & Rotter V. (1997). The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells.  Molecular and Cellular Biology. 1997, 17 (2):713-722.
  • Peled A., Zipori D. & Rotter V. (1996). Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells.  Cancer Research. 1996, 56 (9):2148-2156.
  • Peled A., Schwartz D., Elkind N., Wolkowicz R., Li R. & Rotter V. (1996). The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells.  Oncogene. 1996, 13 (8):1677-1685.
  • Ronen D., Schwartz D., Teitz Y., Goldfinger N. & Rotter V. (1996). Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels.  Cell Growth and Differentiation. 1996, 7 (1):21-30.
  • Reisman D., Bálint É., Loging W. T., Rotter V. & Almon E. (1996). A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells.  Genomics. 1996, 38 (3):364-370.
  • Schreiber L., Sharabi Y., Schwartz D., Goldfinger N., Brodie C., Rotter V. & Shoham J. (1996). Induction of apoptosis and p53 expression in immature thymocytes by direct interaction with thymic epithelial cells.  Scandinavian Journal of Immunology. 1996, 44 (4):314-322.
  • Eizenberg O., FaberElman A., Gottlieb E., Oren M., Rotter V. & Schwartz M. (1996). p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells.  Molecular and Cellular Biology. 1996, 16 (9):5178-5185.
  • ELKIND N., Goldfinger N. & Rotter V. (1995). Spot-1, a novel NLS-binding protein that interacts with p53 through a domain encoded by p(CA)n repeats.  Oncogene. 1995, 11 (5):841-851.
  • TENDLER Y., SCHWARTZ Y., RESHEF R., SHASHA S., Rotter V. & SHKOLNIK T. (1995). IMMUNOHISTOCHEMICAL DETECTION OF P53 PROTEIN EXPRESSION IN HPV-INDUCED CONDYLOMA ACUMINATUM.  Acta Dermato-Venereologica. 1995, 75 (3):177-179.
  • WOLKOWICZ R., ELKIND N., RONEN D. & Rotter V. (1995). The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes.  Oncogene. 1995, 10 (6):1167-1174.
  • EIZENBERG O., FABER-ELMAN A., GOTTLIEB E., Oren M., Rotter V. & Schwartz M. (1995). Direct involvement of p53 in programmed cell death of oligodendrocytes.  EMBO Journal. 1995, 14 (6):1136-1144.
  • ALONI-GRINSTEIN R., SCHWARTZ D. & Rotter V. (1995). Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression.  EMBO Journal. 1995, 14 (7):1392-1401.
  • PELLER S., Halevy A., SLUTZKI S., KOPILOVA Y. & Rotter V. (1995). p53 mutations in matched primary and metastatic human tumors.  Molecular Carcinogenesis. 1995, 13 (3):166-172.
  • Wolkowicz R., Peled A., Elkind N. B. & Rotter V. (1995). Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form.  Proceedings of the National Academy of Sciences of the United States of America. 1995, 92 (15):6842-6846.
  • Peller S., Kopilova Y., Slutzki S., Halevy A., Kvitko K. & Rotter V. (1995). A Novel Polymorphism in Intron 6 of the Human p53 Gene: A Possible Association with Cancer Predisposition and Susceptibility.  DNA and Cell Biology. 1995, 14 (12):983-990.
  • Rotter V., ALONIGRINSTEIN R., SCHWARTZ D., ELKIND N., SIMONS A., WOLKOWICZ R., LAVIGNE M., BESERMAN P., KAPON A. & Goldfinger N. (1994). Does wild-type p53 play a role in normal cell differentiation?.  Seminars in Cancer Biology. 1994, 5 (3):229-236.
  • Barak Y., LUPO A., Zauberman A., JUVEN T., ALONIGRINSTEIN R., GOTTLIEB E., Rotter V. & Oren M. (1994). Targets for transcriptional activation by wild-type p53: Endogenous retroviral LTR, immunoglobulin-like promoter, and an internal promoter of the mdm2 gene.  Cold Spring Harbor Symposia on Quantitative Biology. 1994, 59 :225-235.
  • Tendler Y., Reshef R., Cohen I., Barzilai M., Shasha S. M., Rotter K. & Shkolnik T. (1994). Histochemical studies of progressive p53 mutations during colonic carcinogenesis in sprague-dawley rats induced by n-methyl-n-nitro- nitrosoguanidine or azoxymethane.  Pathobiology. 1994, 62 (5-6):232-237.
  • Prokocimer M. & Rotter V. (1994). Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages.  Blood. 1994, 84 (8):2391-2411.
  • FOORD O., NAVOT N. & Rotter V. (1993). Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein.  Molecular and Cellular Biology. 1993, 13 (3):1378-1384.
  • Rotter V., SCHWARTZ D., ALMON E., Goldfinger N., KAPON A., MESHORER A., DONEHOWER L. & LEVINE A. (1993). Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome.  Proceedings of the National Academy of Sciences of the United States of America. 1993, 90 (19):9075-9079.
  • RAGIMOV N., KRAUSKOPF A., NAVOT N., Rotter V., Oren M. & ALONI Y. (1993). Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif.  Oncogene. 1993, 8 (5):1183-1193.
  • SCHWARTZ D., Goldfinger N. & Rotter V. (1993). Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes.  Oncogene. 1993, 8 (6):1487-1494.
  • ALONIGRINSTEIN R., ZANBAR I., ALBOUM I., Goldfinger N. & Rotter V. (1993). Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.  Oncogene. 1993, 8 (12):3297-3305.
  • REISMAN D., ELKIND N., ROY B., BEAMON J. & Rotter V. (1993). C-MYC TRANS-ACTIVATES THE P53 PROMOTER THROUGH A REQUIRED DOWNSTREAM CACGTG MOTIF.  Cell Growth & Differentiation. 1993, 4 (2):57-65.
  • ALMON E., Goldfinger N., KAPON A., SCHWARTZ D., LEVINE A. & Rotter V. (1993). Testicular tissue-specific expression of the p53 suppressor gene.  Developmental Biology. 1993, 156 (1):107-116.
  • Reisman D. & Rotter V. (1993). The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene.  Nucleic Acids Research. 1993, 21 (2):345-350.
  • Landesman Y., Pagano M., Draetta G., Rotter V., Fusenig N. E. & Kimchi A. (1992). Modifications of cell cycle controlling nuclear proteins by transforming growth factor β in the HaCaT keratinocyte cell line.  Oncogene. 1992, 7 (8):1661-1665.
  • RONEN D., TEITZ Y., Goldfinger N. & Rotter V. (1992). Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses.  Nucleic Acids Research. 1992, 20 (13):3435-3441.
  • Rotter V. & Prokocimer M. (1991). p53 and human malignancies.  Advances in Cancer Research. 1991, 57 :257-272.
  • SHAULSKY G., Goldfinger N., Peled A. & Rotter V. (1991). INVOLVEMENT OF WILD-TYPE P53 PROTEIN IN THE CELL-CYCLE REQUIRES NUCLEAR-LOCALIZATION.  Cell Growth & Differentiation. 1991, 2 (12):661-667.
  • RONEN D., Rotter V. & REISMAN D. (1991). Expression from the murine p53 promoter is mediated by factor binding to a downstream helix-loop-helix recognition motif.  Proceedings of the National Academy of Sciences of the United States of America. 1991, 88 (10):4128-4132.
  • SHAULSKY G., Goldfinger N., Peled A. & Rotter V. (1991). Involvement of wild-type p53 in pre-B-cell differentiation in vitro.  Proceedings of the National Academy of Sciences of the United States of America. 1991, 88 (20):8982-8986.
  • SHAULSKY G., Goldfinger N., TOSKY M., LEVINE A. & Rotter V. (1991). Nuclear localization is essential for the activity of p53 protein.  Oncogene. 1991, 6 (11):2055-2065.
  • FOORD O., BHATTACHARYA P., Reich Z. & Rotter V. (1991). A DNA binding domain is contained in the C-terminus of wild type p53 protein.  Nucleic Acids Research. 1991, 19 (19):5191-5198.
  • TRAKHTENBROT L., KELMAN Z., Rotter V. & HARANGHERA N. (1990). CHROMOSOMAL MAPPING OF THE MURINE C-ABL PROTOONCOGENE BY INSITU HYBRIDIZATION.  Leukemia. 1990, 4 (2):136-137.
  • SHAULSKY G., Goldfinger N., Ben-Ze'ev A. & Rotter V. (1990). NUCLEAR ACCUMULATION OF P53 PROTEIN IS MEDIATED BY SEVERAL NUCLEAR-LOCALIZATION SIGNALS AND PLAYS A ROLE IN TUMORIGENESIS.  Molecular and Cellular Biology. 1990, 10 (12):6565-6577.
  • SHAULSKY G., Ben-Ze'ev A. & Rotter V. (1990). Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells.  Oncogene. 1990, 5 (11):1707-1711.
  • Reisman D. & Rotter V. (1989). Two promoters that map to 5'-sequences of the human p53 gene are differentially regulated during terminal differentiation of human myeloid leukemic cells.  Oncogene. 1989, 4 (8):945-953.
  • Reisman D. & Rotter V. (1989). Induced expression from the Moloney murine leukemia virus long terminal repeat during differentiation of human myeloid cells is mediated through its transcriptional enhancer.  Molecular and Cellular Biology. 1989, 9 (8):3571-3575.
  • KELMAN Z., PROKOCIMER M., PELLER S., KAHN Y., RECHAVI G., Manor Y., Cohen A. & Rotter V. (1989). Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia.  Blood. 1989, 74 (7):2318-2324.
  • Eliyahu D., Goldfinger N., PINHASIKIMHI O., SHAULSKY G., SKURNIK Y., ARAI N., Rotter V. & Oren M. (1988). METH-A FIBRO-SARCOMA CELLS EXPRESS 2 TRANSFORMING MUTANT P53 SPECIES.  Oncogene. 1988, 3 (3):313-321.
  • REISMAN D., Greenberg M. & Rotter V. (1988). Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1..  Proceedings of the National Academy of Sciences of the United States of America. 1988, 85 (14):5146-5150.
  • POHL J., Goldfinger N., RADLERPOHL A., Rotter V. & SCHIRRMACHER V. (1988). p53 increases experimental metastatic capacity of murine carcinoma cells.  Molecular and Cellular Biology. 1988, 8 (5):2078-2081.
  • SHOHAT O., Greenberg M., REISMAN D., Oren M. & Rotter V. (1987). Inhibition of cell growth mediated by plasmids encoding p53 anti-sense.  Oncogene. 1987, 1 (3):277-283.
  • Nicolson G. L., LaBiche R. A., Frazier M. L., Blick M., Tressler R. J., Reading C. L., Irimura T. & Rotter V. (1986). Differential expression of metastasisassociated cell surface glycoproteins and mRNA in a murine large cell lymphoma.  Journal of Cellular Biochemistry. 1986, 31 (4):305-312.
  • MILLER C., MOHANDAS T., WOLF D., PROKOCIMER M., Rotter V. & KOEFFLER H. (1986). Human p53 gene localized to short arm of chromosome 17.  Nature. 1986, 319 (6056):783-784.
  • Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N. & Rotter V. (1986). Molecular basis for heterogeneity of the human p53 protein.  Molecular and Cellular Biology. 1986, 6 (12):4650-4656.
  • ARAI N., NOMURA D., YOKOTA K., WOLF D., BRILL E., SHOHAT O. & Rotter V. (1986). Immunologically distinct p53 molecules generated by alternative splicing..  Molecular and Cellular Biology. 1986, 6 (9):3232-3239.
  • PROKOCIMER M., SHAKLAI M., BENBASSAT H., WOLF D., Goldfinger N. & Rotter V. (1986). Expression of p53 in human leukemia and lymphoma.  Blood. 1986, 68 (1):113-118.
  • Rotter V., Wolf D., Blick M. & Nicolson G. L. (1985). Expression of abl and other oncogenes is independent of metastatic potential in Abelson virus-transformed malignant murine large cell lymphoma.  Clinical & Experimental Metastasis. 1985, 3 (2):77-86.
  • Rotter V. & Wolf D. (1985). Biological and Molecular Analysis of P53 Cellular-Encoded Tumor Antigen.  Advances in Cancer Research. 1985, 43 (C):113-141.
  • Wolf D. & Rotter V. (1985). Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.  Proceedings of the National Academy of Sciences of the United States of America. 1985, 82 (3):790-794.
  • WOLF D., HARRIS N., Goldfinger N. & Rotter V. (1985). Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule.  Molecular and Cellular Biology. 1985, 5 (1):127-132.
  • Wolf D., Laver-Rudich Z. & Rotter V. (1985). In vitro expression of human p53 cDNA clones and characterization of the cloned human p53 gene.  Molecular and Cellular Biology. 1985, 5 (8):1887-1893.
  • Rotter V., Wolft D. & Nicolson G. L. (1984). The expression of transformation-related protein p53 and p53-containing mRNA in murine RAW117 large cell lymphoma cells of differing metastatic potential.  Clinical & Experimental Metastasis. 1984, 2 (3):199-204.
  • PARADA L., LAND H., WEINBERG R., WOLF D. & Rotter V. (1984). Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.  Nature. 1984, 312 (5995):649-651.
  • Rotter V., WOLF D., PRAVTCHEVA D. & RUDDLE F. (1984). Chromosomal assignment of the murine gene encoding the transformation-related protein p53.  Molecular and Cellular Biology. 1984, 4 (2):383-385.
  • Wolf D., Admon S., Oren M. & Rotter V. (1984). Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species..  Molecular and Cellular Biology. 1984, 4 (3):552-558.
  • Wolf D. & Rotter V. (1984). Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences.  Molecular and Cellular Biology. 1984, 4 (7):1402-1410.
  • Rotter V., Friedman H., Katz A., Zerivitz K. & Wolf D. (1983). Variation in antigenic determinants of p53 transformation-related protein obtained from various species.  Journal of Immunology. 1983, 131 (1):329-333.
  • Rotter V., Abutbul H. & Wolf D. (1983). The presence of p53 transformationrelated protein in AbMuLV transformed cells is required for their development into lethal tumors in mice.  International Journal of Cancer. 1983, 31 (3):315-320.
  • Rotter V., Abutbul H. & Ben-Ze'ev A. (1983). P53 transformationrelated protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of nontransformed fibroblasts.  The EMBO Journal. 1983, 2 (7):1041-1047.
  • Rotter V. (1983). p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells.  Proceedings Of The National Academy Of Sciences Of The United States Of America-Biological Sciences. 1983, 80 (9 I):2613-2617.
  • Rotter V. & Trainin N. (1979). Role of thymic hormone (THF) and of a thymic plasma recirculating factor (TPRF) in the modulation of human lymphocyte response to PHA and Con A.  Journal of Immunology. 1979, 122 (2):414-420.
  • Rotter V., Yakir Y. & Trainin N. (1979). Role of L-alanine in the response of human lymphocytes to PHA and Con A.  Journal of Immunology. 1979, 123 (4):1726-1731.
  • Rotter V., Fink A. & Trainin N. (1978). In vitro allogeneic response of human lymphocytes dependent upon dialyzable plasma components and a thymic hormone, THF.  Cellular Immunology. 1978, 36 (2):242-250.
  • Rotter V. & Trainin N. (1977). Effect of thymic hormone on the response of different lymphoid cell populations to T mitogens.  Israel Journal of Medical Sciences. 1977, 13 (4):363-370.
  • ZAIZOV R., VOGEL R., Cohen I., VARSANO I., SHOHAT B., Rotter V. & Trainin N. (1977). Thymic hormone (THF) therapy in immunosuppressed children with lymphoproliferative neoplasia and generalized varicella.  Biomedicine Express. 1977, 27 (3):105-108.
  • VARSANO I., SCHONFELD T. M., MATOTH Y., SHOHAT B., ENGLANDER T., ROTTER V. & TRAININ N. (1977). SEVERE DISSEMINATED ADENOVIRUS INFECTION SUCCESSFULLY TREATED WITH A THYMIC HUMORAL FACTOR, THF.  Acta Paediatrica Scandinavica. 1977, 66 (3):329-331.
  • Rotter V., Schlesinger M., Kalderon R. & Trainin N. (1976). Response of human lymphocytes to PHA and con A, dependent on and regulated by THF, and thymic hormone.  Journal of Immunology. 1976, 17 (5 (II)):1927-1932.
  • Levo Y., Rotter V. & Ramot B. (1975). Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.  Biomedicine. 1975, 23 (6):198-200.
  • Rotter V. & Trainin N. (1975). Elimination of suppressor T-cells in mice undergoing a graft-versus-host reaction expressed by increased response to polyvinylpyrrolidone (PVP).  Cellular Immunology. 1975, 18 (1):199-209.
  • Rotter V. & Trainin N. (1975). Increased mitogenic reactivity of normal spleen cells to T lectins induced by thymus humoral factor (THF).  Cellular Immunology. 1975, 16 (2):413-421.
  • Rotter V. & Trainin N. (1975). Inhibition of tumor growth in syngeneic chimeric mice mediated by a depletion of suppressor T cells.  Transplantation. 1975, 20 (1):68-74.
  • Trainin N., Levo Y. & Rotter V. (1974). Resistance to hydrocortisone conferred upon thymocytes by a thymic humoral factor.  European Journal of Immunology. 1974, 4 (9):634-637.
  • Rotter V. & Trainin N. (1974). Thymus cell population exerting a regulatory function in the immune response of mice to polyvinyl pyrrolidone.  Cellular Immunology. 1974, 13 (1):76-86.
  • LONAI P., MOGILNER B., Rotter V. & Trainin N. (1973). Studies on the effect of a thymic humoral factor on differentiation of thymusderived lymphocytes.  European Journal of Immunology. 1973, 3 (1):21-26.
  • Rotter V., Globerson A., Nakamura I. & Trainin N. (1973). Studies on characterization of the lymphoid target cell for activity of a thymus humoral factor.  Journal of Experimental Medicine. 1973, 138 (1):130-142.